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Abstract
Background: Lung cancer is the leading cause of cancer-related death worldwide. Genetic and epigenetic
alterations have been identified frequently in lung cancer, such as promoter methylation, gene mutations and
genomic amplification. However, the interaction between genetic and epigenetic events and their significance in
lung tumorigenesis remains poorly understood.
Methods: We determined the promoter methylation of 6 genes and PIK3CA amplification using quantitative
methylation-specific PCR (Q-MSP) and real-time quantitative PCR, respectively, and explore the association of
promoter methylation with PIK3CA amplification in a large cohort of clinically well-characterized non-small cell lung
cancer (NSCLC).
Results: Highly frequent promoter methylation was observed in NSCLC. With 100% diagnostic specificity, excellent
sensitivity, ranging from 45.8 to 84.1%, was found for each of the 6 genes. The promoter methylation was
associated with histologic type. Methylation of CALCA, CDH1, DAPK1, and EVX2 was more common in squamous
cell carcinomas (SCC) compared to adenocarcinomas (ADC). Conversely, there was a trend toward a higher
frequency of RASSF1A methylation in ADC than SCC. In addition, PIK3CA amplification was frequently found in
NSCLC, and was associated with certain clinicopathologic features, such as smoking history, histologic type and
pleural indentation. Importantly, aberrant promoter methylation of certain genes was significantly associated with
PIK3CA amplification.
Conclusions: Our data showed highly frequent promoter methylation and PIK3CA amplification in Chinese NSCLC
population, and first demonstrated the associations of gene methylation with PIK3CA amplification, suggesting that
these epigenetic events may be a consequence of overactivation of PI3K/Akt pathway.
Keywords: Promoter methylation PI3K/Akt pathway, PIK3CA amplification, non-small cell lung cancer (NSCLC), clini-
copathologic characteristics
Background
Lung cancer is the number one cancer killer in China
and soon will reach epidemic levels worldwide [1]. Epi-
demiological evidence has documented that approxi-
mately 41.8 men and 19.3 women per 100,000 Chinese
individuals died of lung cancer in 2005 [2]. This disease
is largely associated with smoking. While in developed
countries smoking rates are decreasing, the use of
tobacco products is increasing in the developing coun-
tries. In combination with a spike in the number of lung
cancer cases in never smokers, this ensures that lung
cancer will remain a major health problem [3]. Lung
cancer is clinically divided into two subtypes, small cell
lung cancer (SCLC) and non-small cell lung cancer
(NSCLC). The latter is the most common type, account-
ing for 85-90% of the total cases [3]. Although recent
studies have shown that adjuvant chemotherapy
improves survival in completely resected NSCLC [4,5],
only 5-15% of treated individuals ultimately benefit [6].
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well know, the disease has proven difficult to diagnosis
early and treat successfully, reflecting limited advances
in our understanding of the molecular mechanisms
underlying lung carcinogenesis.
Currently, mutations in the K-ras oncogene, p53
tumor suppressor gene, and epidermal growth factor
receptor (EGFR) gene have been found frequently in
lung tumors and implicated in lung carcinogenesis [7-9].
In addition, genomic abnormalities represent another
major signature of neoplastic transformation and tumor
progression [10]. Chromosome copy number abnormal-
ities in lung cancer have been frequently identified using
comparative genomic hybridization (CGH) assay [11,12],
including genomic amplification of PIK3CA which codes
the phosphatidylinositol-3-kinase (PI3K) catalytic subu-
nit a [13]. PIK3CA is generally activated by a series of
cell surface tyrosine kinase receptors [14]. Upon activa-
tion, PIK3CA binds to its heterodimer, p85, and pro-
motes the phosphorylation of Akt. Activated Akt
phosphorylates down-stream protein effectors and
amplifies the signaling cascade, enhancing cell prolifera-
tion and survival [15]. The previous studies have shown
that PIK3CA amplification was more frequently
observed in squamous cell carcinomas (SCC) than ade-
nocarcinomas (ADC), which was closely associated with
increased Akt activity in SCC [12,13], suggesting that
PIK3CA amplification, in addition to K-ras and EGFR
mutations, may be another major cause of overactivation
of PI3K/Akt pathway that promotes lung tumorigenesis.
In addition to genetic factors, promoter methylation is
an alternative mechanism underlying inactivation of
tumor-associated genes in lung carcinogenesis [16,17].
Currently, methylated gene profiles have been widely
studied in lung cancer [18,19]. Of note, although it has
been suggested that epigenetic alterations of genes can
occur as a consequence of, or coexist with, aberrant sig-
naling of certain oncogenic pathways activated by
genetic alterations, such as PIK3CA amplification, EGFR
mutation and K-ras mutation [20,21], the interaction
between genetic and epigenetic alterations in lung can-
cer still remains poorly understood.
In the present study, we used quantitative methyla-
tion-specific PCR (Q-MSP) to evaluate methylation
levels of a panel of cancer-related genes in a cohort of
clinically well-characterized NSCLC samples, including
CALCA, CDH1, DAPK1, EVX2, PAX6,a n dRASSF1A,
and further explore the association of promoter methy-
lation of these genes with PIK3CA amplification.
Methods
Clinical samples and DNA isolation
With the institutional review board approval, 96 tissue
samples from 96 NSCLC patients and 15 controls from
non-cancerous respiratory diseases, including 6 patients
with pulmonary tuberculosis, 4 patients with brochiecta-
sis and 5 patients with pulmonary abscess, were ran-
domly obtained from the First Affiliated Hospital of
China Medical University, P.R. China. Of these controls,
the mean age was 60.7 years, and over 60 years of age
accounts for 47%. Sixty-seven percent of controls were
male. Seventy-three percent of controls had a history of
smoking. The clinicopathologic characteristics of
NSCLC cases are shown in Table 1. None of these
NSCLC patients received chemotherapy and radiother-
apy before the surgery. Informed consent was obtained
from each NSCLC patient before the surgery. All of the
Table 1 Clinicopathologic features of NSCLC cases
Characteristics No. of patients (%)
Gender
Male 66 (69)
Female 30 (31)
Age (mean years ± S.D.) 58.9 ± 9.2
≤ 60 56 (58)
> 60 40 (42)
Smoking history
No 30 (31)
Yes 66 (69)
Tumor size (mean cm ± S.D.) 3.9 ± 1.7
1-3 37 (38)
3-5 44 (46)
> 5 15 (16)
Histologic type
Adenocarcinoma (ADC) 30 (31)
Squamous (SSC) 66 (69)
Histologic stage
I 54 (56)
II 32 (34)
III 10 (10)
Lymph node metastasis
No 70 (73)
Yes 26 (27)
Pleural indentation
No 75 (78)
Yes 21 (22)
Invasion or Adhesion
No 65 (68)
Yes 31 (32)
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Page 2 of 11samples were reviewed by a pathologist at Department
of Pathology of the Hospital to identify histologic type
and other tumor characteristics. The samples were trea-
ted and genomic DNA was isolated from paraffin-
embedded tissues as previously described [22], using
xylene to remove pareffin and sodium dodecyl sulfate
(SDS) and proteinase K to digest tissues, followed by
phenol-chloroform extraction and ethanol precipitation
of DNA.
Sodium bisulfite treatment
Bisulfite processing of DNA was performed in principle
as described previously [20]. Briefly, a final volume of
20 μlo fH 2Oc o n t a i n i n g2μg genomic DNA, 10 μgs a l -
mon sperm DNA, and 0.3 M NaOH was incubated at
50°C for 20 min to denature the DNA. The bisulfite
reaction was performed in 500 μlo faf r e s h l yp r e p a r e d
solution containing 3 M sodium bisulfite (Sigma, Saint
Louis, MO), 10 mM hydroquinone (Sigma, Saint Louis,
M O )a t7 0 ° Cf o r2 - 3h .D N Aw a ss u b s e q u e n t l yr e c o v -
ered by a Wizard DNA Clean-Up System (Promega
Corp., Madison, WI) following the instructions of the
manufacturer, and desulphonated in 0.2 M NaOH at
37°C for 10 minutes, neutralized by ammonium acetate,
alcohol precipitated, dried, and then dissolved in 30 μl
of deionized H2O. After bisulfite processing, all
unmethylated cytosine residues converted to uracil,
whereas the methylated cytosine residues remained
unchanged. Bisulfited-modified DNA samples were
stored at -80°C until use.
Quantitative methylation-specific PCR (Q-MSP) assay
The Q-MSP protocol was as described previously [20].
Briefly, the Q-MSP assay was carried out in a final
volume of 20 μl on a 96-well plate using an ABI 7500
Fast Real-Time PCR System (Perkin-Elmer, Foster City,
CA). The reaction mixture contained 3 μlb i s u l f i t e - t r e a -
ted DNA, 600 nM each primer, 200 nM TaqMan probe,
5 . 5m MM g C l 2 ,0 . 6Up l a t i n u mTaq polymerase, 200
μM each of deoxyguanosine triphosphate, and 2% Rox
reference. Q-MSP was run at 95°C for 2 min, followed
by 40 cylces at 95°C for 15 sec and 60°C for 1 min.
Each sample was run in triplicate and each plate con-
tained multiple water blanks and serial dilutions of posi-
tive methylated controls to construct the standard
curve. Methylated DNA samples, used as positive con-
trols, were obtained by in vitro treatment of leukocyte
DNA with Sss I DNA methylase (New Engliand Biolabs,
Beverly, MA). To determine the relative level of methy-
lation, the ratio of the value of the gene of interest over
the value of the internal reference gene (b-actin)w a s
used in the current detection system. The primers and
TaqMan probes used in the present study were pre-
sented in Table 2.
Copy number analysis of PIK3CA with real-time
quantitative PCR
We used a real-time quantitative PCR technique to ana-
lyze the copy number of PIK3CA gene on an ABI 7500
Fast Real-Time PCR System (Perkin-Elmer, Foster City,
CA) as described previously [22]. This method was well
established and validated by florescence in situ hybridi-
zation (FISH) [22,23], which has been widely used in
the various cancers [22-25]. Specific primers and probes
were designed using Primer Express 3.0 (Applied Bio-
systems) to amplify PIK3CA and b-actin genes as
described previously [22]. The reaction of quantitative
PCR was repeated twice, and b-actin was run in parallel
to normalize the amount of input DNA. A standard
curve was established using serial dilutions of normal
l e u k o c y t eD N Aw i t haq u a n t i t yr a n g eo f0 . 0 1 - 2 0n g / μl.
Amplification of PIK3CA gene was defined by a copy
number ≥ 4.
Statistical analysis
A methylation positive result was defined when the
ratio was above a certain cut-off value. The relative
level of methylation varied significantly among the 6
genes and the cut-off points were thus studied for
each gene individually. To define cut-off value of each
gene, we construct receiver operating characteristic
(ROC) curves using the Medcalc Software (MedCalc
Software bvba, Belgium). The area under ROC curve is
a measure of the ability of a continuous marker to
Table 2 Quantitative methylation-specific PCR primer and TaqMan probe sequences used in the present study
Genes Forward primer sequence (5’®3’) Probe sequence (5’®3’) Reverse primer sequence (5’®3’)
CALCA GTTTTGGAAGTATGAGGGTGACG 6FAM-ATTCCGCCAATACACAACAACCAATAAACG-TAMRA TTCCCGCCGCTATAAATCG
CDH1 AATTTTAGGTTAGAGGGTTATCGCGT 6FAM-CGCCCACCCGACCTCGCAT-TAMRA　 TCCCCAAAACGAAACTAACGAC　
DAPK1 GGATAGTCGGATCGAGTTAACGTC　 6FAM-TTCGGTAATTCGTAGCGGTAGGGTTTGG-TAMRA　 CCCTCCCAAACGCCGA　
EVX2 TCGTTGGCGGGTGGGTATAG 6FAM-CTTCACTCCAAACCGCTCCTCATCTCCCG-TAMRA ACGCCGATAACAACCATTTTAACG
PAX6 ATATAGGACGGCGGTTTAGGTTG　 6FAM-CCCAAAATCCGACCGACTCCAACCCCTA-TAMRA　 TTCCGACCGAACGAAAACCTAC　
RASSF1A GCGTTGAAGTCGGGGTTC 　 6FAM-ACAAACGCGAACCGAACGAAACCA-TAMRA 　 CCCGTACTTCGCTAACTTTAAACG 　
b-Actin TGGTGATGGAGGAGGTTTAGTAAGT　 6FAM-ACCACCACCCAACACACAATAACAAACACA-TAMRA　 AACCAATAAAACCTACTCCTCCCTTAA　
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Page 3 of 11accurately classify tumor and non-tumor tissue. Such a
curve is a plot of sensitivity vs. 100 minus specificity
values associated with all dichotomous markers that
can be formed by varying the cut-off values used to
define a marker “positive”. As an useful biomarker for
early diagnosis and prognostic evaluation of diseases,
its specificity should be more important than its sensi-
tivity. Hence, in the present study, cut-offs were
obtained in order to achieve 100% specificity. Factors
(promoter methylation and PIK3CA amplification)
associated with clinicopathological characteristics of
tumor were assessed univariately using the Medcalc
Software (MedCalc Software bvba, Belgium). Similarly,
univariate models were examined the association
between gene methylation and PIK3CA amplification.
Multivariate models were then developed that adjusted
for the most important covariates, including smoking
history, histologic type, and lymph node metastasis.
Sample means were compared using unpaired t-test,
assuming unequal variances, and all tests were two-
tailed. P values <0.05 were considered significant. All
statistical analyses were performed using the SPSS sta-
tistical package (11.5, Chicago, IL, USA).
Results
NSCLC patient profiles
In the present study, we analyzed the promoter methyla-
tion of 6 genes using Q-MSP technique in 96 well-char-
acterized NSCLC patients. As shown in Table 1, the
mean age of all NSCLC cases was 58.9 years, and the
cases with age >60 years accounts for 42%. Males were
more frequent than females (69% vs. 31%). Sixty-nine
percent of cases had a history of smoking. Ninety per-
cent of NSCLC cases had surgical stage I and II disease
and 84% had tumors < 5 cm. By histology, 31% of
patients were ADC, and 69% were SCC. The cases with
lymph node metastasis, pleural indentation and invasion
or adhesion were in 26/96 (27%), 21/96 (22%), and 31/
96 (32%), respectively.
Frequent promoter methylation and PIK3CA amplification
in NSCLC
We used Q-MSP assay to examine promoter methyla-
tion of CALCA, CDH1, DAPK1, EVX2, PAX6,a n d
RASSF1A genes in a large cohort of NSCLC samples. As
shown in Figure 1, the overall methylation level of each
of 6 genes was higher in NSCLC tissues than in non-
cancerous lung tissues, particularly CALCA (P <0 . 0 1 ) ,
CDH1 (P <0 . 0 1 ) ,EVX2 (P < 0.01), PAX6 (P <0 . 0 0 1 ) ,
and RASSF1A (P <0 . 0 5 ) .T od i s t i n g u i s hN S C L Cf r o m
non-cancerous lung tissues, we set up appropriate cut-
off values, and used them to determine diagnostic sensi-
tivity and specificity. As shown in Figure 2, with 100%
diagnostic specificity for each of the 6 genes, the sensi-
tivity of CALCA, CDH1, DAPK1, EVX2, PAX6,a n d
RASSF1A was 69.2%, 45.8%, 84.1%, 63.6%, 75.7%, and
72.9%, respectively. With a gene copy number of four or
more defined as amplification, we found the incidence
of PIK3CA amplification in NSCLC was 31.3% (30/96)
in the present study. Of note, among all cases with
PIK3CA amplification, only two cases were ADC, the
remaining cases were SCC.
Association of promoter methylaton and PIK3CA
amplification with clinicopathological characteristics in
NSCLC
Among all clinicopathologic characteristics, promoter
methylation was associated with histologic type (Figure
3). The univariate analyses showed that methylation of
CALCA, CDH1, DAPK1,a n dEVX2 was common in
SCC compared to ADC, particularly in CDH1 (OR =
2.63, 95% CI = 1.05-6.60) and DAPK1 (OR = 6.64, 95%
CI = 1.85-23.8) (Figure 3). Conversely, there was a
trend toward a higer frequency of RASSF1A methyla-
tion in ADC than SCC (Figure 3). Moreover, there was
a trend toward a positive association between CALCA
methylation and invasion or adhesion (OR = 2.44, 95%
CI = 0.88-6.79). Similarly, there was a trend toward a
higher frequency of DAPK1 methylaton in patients
with lymph node metastasis than without metastasis
(OR = 5.17, 95% CI = 0.64-42.0) (Figure 3). Of interest,
RASSF1A methylation was negatively associated with
smoking history, lymph node metastasis, and invasion
or adhesion, respectively, although these associations
did not reach statistical difference (Figure 3), suggest-
ing that RASSF1A methylation may be an early event
in lung tumorigenesis, which further confirmed a pre-
vious study. However, no association was found
between promoter methylation and other clinoco-
pathologic characteristics, including gender, age, quan-
tity of cigarette smoking, tumor size, and pleural
indentation (data not shown).
Similar to a previous study [25], PIK3CA gene was
more frequently amplified in NSCLC, and was not
amplified in non-cancerous lung tissues in the present
study. The results showed that there was a trend toward
a higher frequency of PIK3CA amplification in males
than females (24/66 in males and 6/30 in females) (Fig-
ure 4). PIK3CA amplification was significantly frequent
in smokers compared to never-smokers (25/66 in smo-
kers and 5/30 in never-smokers; OR = 3.05, 95% CI =
1.03-8.90), and in SCC compared to in ADC (28/66 in
SCC and 2/30 in ADC; OR = 10.3, 95% CI = 2.27-47.0)
(Figure 4). Of note, there was a trend toward a negative
association between PIK3CA amplification and pleural
indentation in NSCLC (Figure 4).
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Page 4 of 11Association of promoter methylation with PIK3CA
amplification in NSCLC
To explore the relationship between promoter methyla-
tion with PIK3CA amplification in NSCLC, all tumor
samples were divided into two groups, one with PIK3CA
amplification and the other without PIK3CA amplifica-
tion. As shown in Figure 5, methylation level of CALCA
(P = 0.0006) and EVX2 (P = 0.001) was significantly
higher in the former group than in the latter group.
However, there was not significant association between
PIK3CA amplification and methylation level of other
genes, including CDH1, DAPK1, PAX6,a n dRASSF1A
(Figure 5), suggesting a specific association of PIK3CA
amplification with methylation of CALCA and EVX2 in
NSCLC.
Univariate analyses indicated that promoter methyla-
tion of CALCA was significantly positively associated
with PIK3CA amplification (OR = 3.05, 95% CI = 1.03-
8.99). Conversely, promoter methylation of PAX6 was
significantly negatively associated with PIK3CA amplifi-
cation (OR = 0.27, 95% CI = 0.10-0.72). In order to
assess the independent associations between promoter
methylation of these genes and PIK3CA amplification,
smoking history, histologic type, and lymph node
metastasis, we conducted multiple multivariable logistic
regressions (Table 3). Similarly, the results showed that
there was a trend toward a positive association between
CALCA methylation and PIK3CA amplification (OR =
2.55, 95% CI = 0.81-8.08). Promoter methylation of
PAX6 was significantly negatively associated with
PIK3CA amplification (OR = 0.19, 95% CI = 0.06-0.62)
(Table 3).
Discussion
In the present study, we investigated the promoter
methylation of the 6 genes in a large cohort of well-
characterized NSCLC samples using Q-MSP technique
and their relationships to PIK3CA amplification. Promo-
ter methylation of these genes, as a mechanism for their
silencing, has been frequently observed in NSCLC, parti-
cularly CALCA, CDH1, DAPK1,a n dRASSF1A [26-28].
In addition, this study also involved two new methyla-
tion markers, EVX2 and PAX6, which were highly speci-
fic for tumor-associated methylation, and little or no
methylation was observed in tumor-adjacent normal
lung tissue [29]. Our findings showed that the overall
methylation level from 5 of 6 genes in tumor tissues
was significant higher than in non-cancerous lung









7 1
(9;
3  

 






7 1
5$66)$
3  

5
H
O
D
W
L
Y
H

P
H
W
K
\
O
D
W
L
R
Q

O
H
Y
H
O


*
H
Q
H
V

£
£
£
£

D
F
W
L
Q










7 1
&$/&$
3  







7 1
&'+
3  








7 1
'$3.
3  









7 1
3$;
3 



Figure 1 The overall methylation levels of the 6 genes in NSCLC. Q-MSP assay was performed as described in Methods. The relative
methylation level (on Y axis) is represented by ratios of candidate gene/b-actin (CALCA, CDH1, DAPK1, and RASSF1A × 1000; EVX2 and PAX6 ×
100). Horizonal lines indicate a 95% confidence interval for the sample mean. T, tumor tissues; N, non-cancerous lung tissues. *, P < 0.05; **, P <
0.01; ***, P < 0.001.
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Page 5 of 11tissues, including CALCA, CDH1, EVX2, PAX6,a n d
RASSF1A. With 100% diagnostic specificity, excellent
sensitivity, ranging from 45.8 to 84.1%, was obtained for
each of the 6 genes. However, the analysis of hyper-
methylation still had a limitation in the present study,
which the values of hypermethylation were not estab-
lished a priori, but were calculated to maximize sensitiv-
ity given 100% specificity, the resulting sensitivities
might be biased overestimates. To obtain non-biased
sensitivity (and specificity) values, cut-offs need to be
validated in a separate independent sample. In the pre-
sent study, we also observed that promoter methylation
of certain genes was associated with histologic type.
Methylation of CALCA, CDH1, DAPK1,a n dEVX2 was
common in SCC compared to ADC, particularly in
CDH1 (OR = 2.63, 95% CI = 1.05-6.60) and DAPK1
(OR = 6.64, 95% CI = 1.85-23.8). Conversely, there was
a trend toward a higher frequency of RASSF1A methyla-
tion in ADC than SCC, which is consistent with a
recent study [26]. Of note, there was a trend toward an
association between methylation of CALCA and DAPK1
and invasion or adhesion and lymph node metastasis,
suggesting that aberrant methylation of these genes is
associated with oncologic outcomes of NSCLC patients.
Similar to a previous study [30], RASSF1A methylation
was negatively associated with smoking history, lymph
node metastasis, and invasion or adhesion, respectively.
In addition, RASSF1A was more frequently methylated
in early tumor stage (data not shown), suggesting that
RASSF1A methylation may be an early event in lung
tumorigenesis.
Although tobacco smoking plays a dominant role in
the development of lung cancer, we did not observe
significant association between promoter methylation
and smoking history in the present study, in agreement
with most studies [31-34]. However, several studies
have reported aberrant methylation of tumor-related
genes was associated with tobacco smoking [32,35,36].
It is possible that smoking-associated lung cancer is
complex disease which involved many unique genetic
and epigenetic events. Thus, better understanding of
the molecular mechanisms underlying this disease
would undoubtedly improve the outcomes of such
patients.
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Figure 2 Receiver operating characteristic (ROC) curves for the 6 genes in NSCLC. Complete DNA methylation data from all NSCLC and
non-cancerous lung tissues were used to construct the ROC curves. The ROC curves plot sensitivity vs. 100-specificity. The determined cut-off
values for CALCA, CDH1, DAPK1, EVX2, PAX6, and RASSF1A were 45.7, 29.0, 0, 23.7, 13.0, and 0, respectively.
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Page 6 of 11It has recently become clear that PI3K/Akt pathway is
frequently activated in human cancers [15,37], and plays
an important role in the regulation of cell growth, pro-
liferation, and survival and is involved in human tumori-
genesis [15]. In recent years, many oncologists have
mainly focused on PIK3CA. In addition to PIK3CA
mutations [38,39], PIK3CA amplification was frequently
found in lung cancer, and promoted lung tumorigenesis
through overactivation of PI3K/Akt signaling pathway
[12,13,25,39]. Similar to the previous studies, in the pre-
sent study, we found high frequency of PIK3CA amplifi-
cation in Chinese NSCLC population. Moreover,
PIK3CA amplification was significantly associated with
smoking history and histologic type, which was more
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0.31 (0.10-0.99)*
0.47 (0.18-1.25)
1.76 (0.53-5.84)
0.44 (0.17-1.11)
Methylated Genes Odds Ratio (95% CI)
Figure 3 Relationship of promoter methylation (Odds Ratios) with tumor characteristics of NSCLC. Multiple univariate logistic-regressions
were performed with the use of methylation data for the 6 genes that were defined as ‘positive’ or ‘negative’ through receiver operating
characteristic (ROC) curves. Details are as described in Methods. *, P < 0.05.
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Figure 4 Relationship of PIK3CA amplification (Odds Ratios) with tumor characteristics of NSCLC. Univariate logistic regression was
performed to evaluate the relationship between PIK3CA amplification and clinicopathological characteristics of NSCLC cases. Details are as
described in Methods. *, P < 0.05.
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Figure 5 Association of promoter methylation of these 6 genes with PIK3CA amplification in NSCLC. Methylation levels of the 6 genes
are represented as described in Figure 1. ‘+’ indicates tumor samples harbor PIK3CA amplification; ‘-’ indicates lack of PIK3CA amplification. *, P <
0.05.
Ji et al. BMC Cancer 2011, 11:147
http://www.biomedcentral.com/1471-2407/11/147
Page 8 of 11frequent in smokers compared to never-smokers, and in
SCC compared to in ADC. Of note, although no statisti-
cal difference was noted, PIK3CA amplification was
negatively associated with pleural indentation in
NSCLC. However, pleural indentation is a well-known
imaging sign on chest computed tomography (CT) that
suggests a possible pleural invasion by peripheral
NSCLC, particularly ADC [40,4 1 ] .I m p o r t a n t l y ,p l e u r a l
involvement was significantly correlated with a poor
prognosis in NSCLC, suggesting that pleural involve-
ment may be one of most important factors to affect on
the prognosis of NSCLC [42]. One possibility to explain
this contradiction is that, PIK3CA gene was more fre-
quently amplified in SCC, not ADC, whereas pleural
indentation is more common in ADC.
It has been suggested the epigenetic alterations might
addict cells to certain oncogenic pathways, predisposing
cells to the accumulations of genetic mutations, which
drives tumor progression [43]. On the other hand, over-
activation of certain oncogenic pathways can affect the
activity of methytransferase, and potentially the methyla-
tion activity and regulation of gene transcription, such
as RAS/RAF/MEK/ERK pathway (MAPK pathway)
[44-47]. Recently, a number of tumor-related genes were
found to be aberrantly methylated in association with
the MAPK pathway overactivated by BRAF mutation in
human cancers, such as hMLH1 in colon cancer [48],
and SLC5A8 in thyroid cancer [49]. Of note, our pre-
vious study showed that PTEN gene was aberrantly
methylated in association with activating genetic altera-
tions in PI3K/Akt pathway, including PIK3CA amplifica-
tion [20]. Moreover, another study showed that the
differences in the evolvement of epigenetic alterations
between the EGFR and K-ras mutation-mediated tumor-
igenesis and suggested that the specific interation of
genetic and epigenetic events in lung tumorigenesis
[21]. In the present study, we found that promoter
methylation of CALCA, EVX2,a n dPAX6 was signifi-
cantly associated with PIK3CA amplification in NSCLC,
however, such association was not seen with other gene
methylation, suggesting that epigenetic alterations of
these three genes may specifically occur as a conse-
quence of overactivation of PI3K/Akt pathway in
NSCLC.
Conclusions
In summary, the results of the present study provided
evidence that multiple genes were aberrantly methylated
during the process of lung tumorigenesis. We found
highly frequent PIK3CA amplification in Chinese
NSCLC cases, but not in non-cancerous lung tissues,
implicating PI3K/Akt pathway in lung tumorigenesis.
Importantly, we have the first time revealed significant
associations of gene methylation with PIK3CA amplifica-
tion in NSCLC, which is consistent with a model which
aberrant methylation and hence silencing of a number
of tumor-related genes, which coexisted with activating
g e n e t i ca l t e r a t i o n so fP I 3 K / A k tp a t h w a y ,m a yb eac o n -
sequence of overactivation of this pathway. Further stu-
dies are needed to explore the molecular mechanisms
underling the link between such genetic and epigenetic
events.
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Table 3 Promoter methylation of individual genes in NSCLC - multivariable models assessing PIK3CA amplification,
smoking history, histologic type, and lymph node metastasis (OR
† and 95%CI)
Genes PIK3CA amplification Smoking history SSC vs. ADC Lymph node metastasis
CALCA 2.55 (0.81-8.08) 1.08 (0.41-2.84) 1.46 (0.51-4.16) 1.38 (0.44-4.31)
CDH1 0.42 (0.16-1.12) 1.35 (0.52-3.47) 4.01 (1.37-11.79)* 0.64 (0.24-1.75)
DAPK1 0.59 (0.11-3.15) 1.45 (0.39-5.30) 6.09 (1.25-29.66)* 2.26 (0.24-21.44)
EVX2 1.31 (0.47-3.69) 0.94 (0.36-2.43) 2.06 (0.73-5.84) 0.92 (0.32-2.65)
PAX6 0.19 (0.06-0.62)* 0.97 (0.31-3.11) 2.62 (0.68-10.14) 0.62 (0.19-2.05)
RASSF1A 1.63 (0.57-4.70) 0.65 (0.22-1.95) 0.32 (0.09-1.18) 0.67 (0.24-1.87)
† OR: odds ratio with 95% confidence interval, adjusted for multiple comparisions.
* Significant at P < 0.05.
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